Title Page

Considering Age Variation when Coining Drugs as High vs Low Hepatic Extraction Ratio

Farzaneh Salem, Khaled Abduljalil, Yoshi Kamiyama and Amin Rostami-Hodjegan

Simcyp Limited (a Certara Company), Sheffield, UK (FS, KA, ARH)

Astellas Pharma Inc, Drug Metabolism & Pharmacokinetics Management Analysis & Pharmacokinetics Labs, 21, Miyukigaoka, Tsukuba-shi, Ibaraki,305-8585, Japan (YK)

Centre for Applied Pharmaceutical Research, Manchester Pharmacy School, The University of Manchester, Stopford Building, Oxford Road, Manchester, M13 9PT, UK (YK, ARH)

Running Title Page

Running Title: Consequences of Age Variation in Hepatic Extraction Ratios

Corresponding Author: Professor Amin Rostami-Hodjegan,

Centre for Applied Pharmaceutical Research, Manchester Pharmacy School, The University of Manchester, Stopford Building, Oxford Road, Manchester, M13 9PT, UK

Tel: +44 (0) 114 292 2330 Fax: +44 (0) 114 292 2333

E-mail: Amin.rostami@manchester.ac.uk

Text pages: 13 (Including References)

Tables: 1 (2 in Supplementary Material)

Figures: 3 (1 in Supplementary Material)

References: 17

Abstract: 254

Introduction: 333

Discussion & conclusions: 837

Abbreviations

AAG, alpha-acid glycoprotein; B:P, Blood to plasma ratio; $CLu_{int,H}$, Hepatic intrinsic clearance of unbound drug; $CL_{H,B}$, Hepatic metabolic clearance; E_H, Hepatic extraction ratio; *fu*, Fraction of drug in plasma unbound; fuB, Unbound drug in blood; MPPGL, Microsomal protein per gram of liver; PopPK, Population pharmacokinetics; Q_H, Hepatic blood flow.

DMD Fast Forward. Published on February 10, 2016 as DOI: 10.1124/dmd.115.067595
This article has not been copyedited and formatted. The final version may differ from this version.

Abstract

Hepatic extraction ratio (E_H) is commonly considered as 'an inherent attribute' of drug. It determines the main physiological and biological elements of the system (patient attributes) which are most significant in inter-individual variability of clearance. E_H consists of three age-dependent parameters: fraction of unbound drug in blood (fu_B), hepatic intrinsic clearance of unbound drug ($CLu_{int,H}$) and hepatic blood flow (Q_H). When age-effects on these elements are not proportional a given drug may shift from so called "high extraction" status to "low extraction". To demonstrate the impact of age-related changes on fu_B, $CLu_{int,H}$ and Q_H, E_H of midazolam and two hypothetical drugs with 10-fold higher and 10-fold lower $CLu_{int,H}$ than midazolam were investigated in paediatrics based on known ontogeny functions. E_H was simulated using Simcyp V14. This was then complemented by a comprehensive literature survey to identify commonly applied covariates in paediatric population pharmacokinetic (PopPK) studies. Midazolam E_H decreased from 0.6 in adults to 0.02 at birth, making its clearance much more susceptible to changes in $CLu_{int,H}$ and fu_B than adults and reducing impact of Q_H on clearance. The drug with 10-fold higher $CLu_{int,H}$ was categorised as high extraction from 4 days old onwards, whilst the drug with 10-fold lower $CLu_{int,H}$ remained low extraction from birth to adulthood. Approximately 50% of collected PopPK studies (n=120) did not consider interaction between age and other covariates. Interaction between covariates and age should be considered as part of studies involving young paediatric patients. E_H cannot be considered as an inherent drug property without considering the effect of age.

DMD Fast Forward. Published on February 10, 2016 as DOI: 10.1124/dmd.115.067595
This article has not been copyedited and formatted. The final version may differ from this version.

Introduction

Hepatic metabolic clearance ($CL_{H,B}$) of intravenously administered drugs is determined by hepatic blood flow (Q_H) and their hepatic extraction ratio (E_H) according to the Equation 1:

$$CL_{H,B} = E_H \times Q_H \qquad \textbf{Equation 1}$$

E_H is calculated from fraction of drug unbound in blood (fu_B), hepatic intrinsic clearance of unbound drug ($CLu_{int,H}$) and Q_H according to Equation 2:

$$E_H = \frac{fu_B \times CLu_{int,H}}{Q_H + (fu_B \times CLu_{int,H})} \qquad \textbf{Equation 2}$$

Extraction ratio of the drug is generally classified as high (>0.7), intermediate (0.3-0.7) or low (<0.3) according to the fraction of drug removed during one pass through the liver. Commonly E_H of a drug is considered as an inherent attribute of the drug and presented with a fixed value. However, this classification does not consider that the parameters in Equation 2 are age-dependent and changes in these parameters will affect E_H. For example, a rise in fu_B, for low E_H drugs increases hepatic metabolic clearance, whereas for high extraction drugs this does not affect metabolic clearance. Unless the age-related physiological changes in fu_B, $CLu_{int,H}$ and Q_H occur in parallel, it is expected that E_H of drugs varies with age. Therefore, a high extraction drug in adults will not necessarily remain a high extraction drug in neonates.

Age-varying E_H can potentially be used as a covariate in clearance models when analysing population pharmacokinetic (PopPK) studies. However, since applying extraction ratio directly in the model might not be straightforward this concept is considered in PopPK models through the interaction between covariate terms in the model. For example, age and body weight are commonly used as covariates in PopPK clearance models where body weight is also affected by age. The interaction between these two covariates should be considered in the model.

The primary aim of this study is to investigate relative differences in E_H with age using *in vivo* midazolam data and two hypothetical high and low extraction drugs through modelling and simulation techniques. We also use the concept of the age varying E_H to examine whether the interaction between covariate terms in modelling clearance have been considered in the PopPK studies.

Materials and Methods

Literature Data collection

Data on midazolam systemic clearance in paediatrics from birth to 17 years were collected from the literature. Literature search strategy and methodology for deconvolution of clearance to arrive at $CL_{H,B}$ from midazolam systemic clearance (using blood to plasma ratio (B:P)) and Q_H based on cardiac output were explained previously (Salem et al., 2014).

Simulations

A drug with 10-fold higher and 10-fold lower $CLu_{int,H}$ than midazolam was designed by multiplying and dividing the deconvoluted midazolam $CLu_{int,H}$ by 10 as proposed by (Salem et al., 2014) to mimic a high and low extraction drug, respectively. Then, using the relevant $CLu_{int,H}$, Q_H and fu_B in Equation 2, E_H was calculated.

A number of simulations in Simcyp Paediatric v14 were carried out for midazolam, a drug with 10-fold higher and 10-fold lower $CLu_{int,H}$ than midazolam to show age related changes in the magnitude of E_H. One hundred subjects were simulated consisting of equal proportion of males and females and combination of age bands (1 day, 1 month, 2 years and 12 years as well as adult). E_H was calculated using Equation 3 from the output data. Mean values of E_H at each age band were plotted against age for each of the simulated drugs.

Calculation of hepatic extraction ratio

Hepatic extraction ratio was calculated from CL_H and Q_H for midazolam and the other two hypothetical drugs assuming well-stirred model using Equation 3;

$$\text{Hepatic Extraction Ratio} = \frac{CL_{H,B}}{Q_H} \qquad \textbf{Equation 3}$$

Sensitivity analysis

Sensitivity analysis was carried out with a view to identify which component of the extraction ratio ($CLu_{int,H}$, Q_H and fu_B) plays the most dominant role in variation of E_H from those of adult

values at any given age. The impact of age dependent Q_H was evaluated by fixing fu_B and $CLu_{int,H}$ (L/h/g of liver) to the adult values for all age ranges. This involved assumptions on lack of any ontogeny for abundance of the enzymes (pmol per mg of microsomal protein) and no age related changes in the level of microsomal protein per gram of liver (MPPGL). The values of $CLu_{int,H}$ (L/h/g of liver) were used to calculated the paediatric $CLu_{int,H}$ values per whole liver by applying age-related liver weight. E_H was plotted against age and patterns were compared. In another set, only fu_B values were fixed to adult values to demonstrate the sensitivity of E_H to age related changes in Q_H and $CLu_{int,H}$ (L/h) without impact of age-related changes in binding. E_H was calculated and plotted against age and compared with the original set of results (where all age-related parameters had been considered).

In order to separate the size related effects (i.e. liver mass and hepatic blood flow) from ontogeny-related factors on E_H, a graphical representation was devised to demonstrate the paediatric values of enzyme abundance relative to adults at given age (in this case CYP3A4) alongside relative values for liver volume, hepatic blood flow and MPPGL.

Population Pharmacokinetic studies (PopPK)

A comprehensive literature survey using Pubmed was carried out to identify commonly used covariates in paediatric PopPK studies for drugs after intravenous administration. No year or journal or language restriction applied to the search process. Collated publications were carefully checked for modelling covariates and the form of the covariates-clearance relationship in the reported model. Studies that considered the interaction between covariates and clearance were identified. Interaction between covariate terms was also considered if the presence of a covariate modifies the impact of another covariate in a multiplicative or exponential way. Where there are different clearance models for different paediatric age ranges, interaction with age is also considered. Interaction between covariate terms was not considered if only one covariate was considered in the final clearance model or if the covariates are in linear additive relationship to the clearance. Corresponding authors were contacted where modelling section was not clear.

Results

Midazolam hepatic extraction ratio

Hepatic extraction ratio of midazolam, after deconvolution of clinical systemic clearance, increased with age. Figure 1 illustrates that midazolam is a low extraction drug until about the age of 10 months. However, in some individuals it remained low at the age of 9 years.

Figure 2 shows E_H increases with age for midazolam and two other hypothetical compounds. The degree of change in E_H with age depends on magnitude of $CLu_{int,H}$ against the given enzyme. As shown in the figure, 10-fold reduction in $CLu_{int,H}$ results in a drug with low hepatic extraction across the paediatric and adult age range whereas 10-fold increase in $CLu_{int,H}$ shifts the drug from so called intermediate to high extraction status.

Sensitivity analysis

Figure 2 compares E_H when all age related components ($CLu_{int,H}$, Q_H and fu_B) considered (solid lines) with a scenario involving no age-related changes in fu_B (dashed lines). As shown in Figure 2 E_H is marginally lower in younger groups if age related fu_B is not considered. However, this might be different for drugs with higher protein binding.

When $CLu_{int,H}$ (L/h/g of liver) and fu_B are fixed to adult values, the changes in E_H will be driven by age-related changes in Q_H and liver weight (Supplemental Figure 1). In this scenario, there are no significant differences between E_H values across paediatric age groups for three drugs since the low activity of CYP3A4 in younger age is not considered.

The rate of change with age for liver volume, hepatic blood flow and MPPGL as a fraction of adult values are shown in Figure 3. This figure shows the changes in underlying parameters of E_H. The changes in blood flow and liver volume relative to adults occurs almost in parallel to each other. Therefore, the discrepancy in Q_H and liver size alone cannot account for the observed differences in E_H instead changes in intrinsic activity to the level of enzyme abundance and to a lesser extent MPPGL are determinants of age-varying E_H. **Error! Reference source not found.** summarises the contributing parameters to E_H that are

reported in Figure 3. Needless to say, if relative values to adult for all these elements had a similar rate of change with age, no age-related differences would have been anticipated in E_H.

Analysis of covariates in population pharmacokinetic (PopPK) studies

A total of 120 PopPK studies were retrieved in paediatric age range (birth to 18 years) for intravenously administered drugs. The interaction between covariate terms was not considered in 50% of the studies (n=60). Table S1 in supplements summarises the most commonly used covariates in the analysed PopPK studies (Supplemental Table 1). Table S2 in supplements shows all the analysed PopPK studies with interaction between covariates (Supplemental Table 2).

Discussion and Conclusions

E_H of the drugs in this study increases with age due to rapid physiological changes in parameters determining E_H after birth including the ontogeny of enzyme abundance and to a lesser extent MPPGL. Although not relevant to the cases represented in this study, ontogeny of plasma proteins can play a significant role in age-related changes of E_H for highly bound, low extraction drugs. As shown previously by several authors, concentration of plasma proteins increases with age whereas unbound fraction of drugs in plasma and therefore in blood decreases with age (Sethi et al., 2015, Johnson et al., 2006 and McNamara and Alcorn, 2002). The ontogeny of plasma protein binding and enzyme abundance on any given compound depends on the extent of binding to particular protein and the importance of that enzymatic pathway to the overall elimination of drug. As a consequence, a drug that is coined a high, low or intermediate hepatic extraction compound in adults is not necessarily going to carry the same extraction category in paediatrics. For the particular case studies in this report, where the binding was not a major factor, and CYP3A4 was the main metabolising enzyme, we demonstrated the switch from high extraction or intermediate extraction to low extraction in neonates and younger children. However, the results from this study should be generalised to other drugs metabolised by other pathways with caution. $CLu_{int,H}$ value is an interplay between the enzyme abundance and kinetic parameters (V_{max} and K_m). The difference in enzyme abundance depending on the pathway and age can be masked or stressed by enzyme kinetic parameters and hence resulting in similar or different $CLu_{int,H}$ and E_H values from what has been shown in this study. Changes in E_H is not confined to age-varying parameters. Induction or inhibition of drug metabolising enzymes for a capacity limited drug and inhibition of drug metabolising enzyme for a flow limited drug can also change the extraction ratio of drugs. In addition changes to Q_H and fu_B due to hemodynamic changes occurring in clinical conditions and progression of disease may affect the extraction ratio of drugs. This consideration can be more important in preterm neonates due to prematurity of metabolic pathways, special populations such as

elderly and pregnancy that can affect free fraction of the drug (f_u), enzyme activity and/or Q_H which ultimately can alter E_H.

Since the determinants of CL (covariates) change with age, it is not right to assume no-interaction between age and covariates. In some of the analysed PopPK studies here, the interaction between covariate terms were not identified by their authors. The reason for lack of such interactions can be the wide age range in some of these studies with limited number of subjects at lower end of spectrum. In addition, several investigations only examined older subsets of children, where the ontogeny of enzymes responsible for metabolism are likely to be fully mature. These investigations are not likely to find that the addition of age into their clearance models provide a better fit. Another reason for lack of interaction origins from unbalanced blood sampling in the early life after birth compared with older children. Some pharmacokinetic studies retrospectively analysed the available samples of drug concentration in blood or plasma where the relevant covariates are not always available. Also some relevant covariates such as f_u may not have been measured in new-borns. Only one PopPK study on morphine concluded an independent clearance model is required for new-borns (Knibbe et al., 2009).

The results in this study suggest that $CLu_{int,H}$ is the most important parameter that affects E_H of drugs. Due to rapid physiological changes after birth and especially in neonatal period E_H of drugs can be significantly affected by changes in $CLu_{int,H}$.

Hepatic extraction also contributes to determination of oral bioavailability of drugs. Currently, there are contradicting evidence as to bioavailability of drugs is different between paediatrics and adults (Harper et al., 1988; Stratchunsky et al., 1991; Pinkerton et al., 1993; Hassan et al., 1994; Fujiwara et al., 1996; Anderson et al., 2002; Crill et al., 2006; Zane and Thakker, 2014). While in clinical practice bioavailability of drugs is assumed to be similar between paediatrics and adults, the current study supports bioavailability also can be an age-dependant parameter and reduce with age since E_H changes with age. Assuming a higher

hepatic extraction and therefore lower bioavailability in neonates, oral clearance can be overestimated in this population and unnecessarily higher doses given to neonates. However, the clinical significance of this under and overestimations is not clear and requires further investigation.

In conclusion, a high extraction drug in adults is not necessarily a high extraction drug in paediatrics. Unless the age-related changes in factors determining E_H occur at the same rate, extraction ratio will be different between paediatrics and adults. More attention should be given to interaction terms of covariate during analysis of such data as the impact of certain physiological covariates might change with age. Further clarification of underlying mechanisms for metabolism (and bioavailability) of drugs should heavily rely on modelling and simulation techniques.

Acknowledgments

The authors are grateful to the reviewers of this manuscript for their considerable input and constructive comments which significantly expanded the scope of this article. We also thank Miss Eleanor Savill for assistance with preparation of the manuscript.

Authorship Contributions:

Participated in research design: Salem, Abduljalil, Kamiyama, Rostami-Hodjegan

Performed data analysis: Salem, Abduljalil, Kamiyama

Wrote or contributed to the writing of the manuscript: Salem, Abduljalil

References

Anderson BJ, Van Lingen RA, Hansen TG, Lin YC and Holford NH (2002) Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. *Anesthesiology* **96:**1336-1345.

Barter ZE, Chowdry JE, Harlow JR, Snawder JE, Lipscomb JC, Rostami-Hodjegan A (2008) Covariation of human microsomal protein per gram of liver with age: Absence of influence of operator and sample storage may justify interlaboratory data pooling. *Drug Metab Dispos* **36**:2405-2409.

Crill CM, Christensen ML, Storm MC and Helms RA (2006) Relative bioavailability of carnitine supplementation in premature neonates. *J Parenter Enter Nutr* **30:**421-425.

Fujiwara Y, Ohune T, Okusaki K, Niitani K, Sumiyoshi H, Takemoto Y, Yamaoka N and Yamakido M (1996) Bioavailability of 50- and 75-mg oral etoposide in lung cancer patients. *Cancer Chemother Pharmacol* **37:**327-331.

Guyton AC (1991) *Cardiac Output, Venous Return, and Their Regulation.* In: Textbook of Medical Physiology, 8th ed. W.B.Saunders Company, Philadelphia.

Harper P, Elwin CE and Cederblad G (1988) Pharmacokinetics of bolus intravenous and oral doses of l-carnitine in healthy-subjects. *Eur J Clin Pharmacol* **35:**69-75.

Hassan M, Ljungman P, Bolme P, Ringden O, Syruckova Z, Bekassy A, Stary J, Wallin I and Kallberg N (1994) Busulfan bioavailability. *Blood* **84:**2144-2150.

Johnson TN, Sabzghabaee A, Rostami-Hodjegan A, Tucker GT (2003) Prediction of age related changes in midazolam clearance in children, in *Proceedings of the British Pharmacological Society Clinical Pharmacology Section 7-10 January 2003, Br J Clin Pharmacol* **55**:418-449

Johnson TN, Tucker GT, Tanner MS and Rostami-Hodjegan A (2005) Changes in Liver Volume from Birth to Adulthood: A Meta-Analysis. *Liver Transpl* **12**:1481-1493.

Johnson TN, Rostami-Hodjegan A and Tucker GT (2006) Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. *Clin Pharmacokinet* **45:**931-956.

Knibbe CA, Krekels EH, Van Den Anker JN, Dejongh J, Santen GW, Van Dijk M, Simons SH, Van Lingen RA, Jacqz-Aigrain EM, Danhof M and Tibboel D (2009) Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. *Clin Pharmacokinet* **48:**371-385.

McNamara PJ and Alcorn J (2002) Protein binding predictions in infants. *AAPS PharmSci* **4**:E4

Pinkerton CR, Dick G and Aherne GW (1993) 24-Hour plasma etoposide profile after oral and intravenous administration in children. *Eur J Cancer* **29A:**1479-1481.

Salem F, Johnson TN, Abduljalil K, Tucker GT and Rostami-Hodjegan A (2014) A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data. *Clin Pharmacokinet* **53:**625-636.

Sethi PK, White CA, Cummings BS, Hines RN, Muralidhara S, Bruckner JV (2015) Ontogeny of plasma proteins, albumin and binding of diazepam, cyclosporine and deltamethrin. *Pediatr Res* Epub ahead of print.

Stratchunsky LS, Nazarov AD, Firsov AA and Petrachenkova NA (1991) Age dependence of erythromycin rectal bioavailability in children. *Eur J Drug Metab Pharmacokinet* **Spec No 3:**321-323.

Zane NR and Thakker DR (2014) A Physiologically Based Pharmacokinetic Model for Voriconazole Disposition Predicts Intestinal First-pass Metabolism in Children. *Clin Pharmacokinet* **53:**1171-1182.

DMD Fast Forward. Published on February 10, 2016 as DOI: 10.1124/dmd.115.067595
This article has not been copyedited and formatted. The final version may differ from this version.

Figure Legends

Figure 1 Hepatic extraction for intravenous midazolam calculated from reports of clinical studies in the literature using ontogeny functions in paediatric subjects and healthy adult volunteers (n=523).

Figure 2 Simulated hepatic extraction in Simcyp v14 shows changes with age for midazolam, a drug with 10-fold higher $CLu_{int,H}$ and a drug with 10-fold lower $CLu_{int,H}$. A high or intermediate extraction drug in adults is not necessarily a high or intermediate exteraction drug in paediatric subjects. Dashed lines are the same E_H values with age when fu_B is remained unchanged (fu_B=0.05). Dotted lines show the limits for high (>0.7) and low (0.3>) extraction.

Figure 3 Age-related variations in parameters defining E_H shown as relative values to corresponding adult level of each parameter. Part (A) indicates the changes in liver size (Johnson et al., 2005), hepatic blood flow (Guyton., 1991) and MPPGL (Barter et al., 2008) which applies to all drugs. Part (B) demonstrates the relative values of serum albumin (Johnson et al., 2003, Johnson et al., 2006 and Sethi et al., 2015), CYP3A4 abundance (of relevance to current study) (Salem et al., 2014) alongside age-variation in serum alpha-acid glycoprotein (AAG) (Johnson et al., 2003 and Johnson et al., 2006) and CYP1A2 abundance (Salem et al., 2014). The impact of the parameters shown in Part (B) will depend on the relative importance of the protein binding to each protein and the role of the specific enzyme to overall elimination.

DMD Fast Forward. Published on February 10, 2016 as DOI: 10.1124/dmd.115.067595
This article has not been copyedited and formatted. The final version may differ from this version.

Tables

Table 1. Examples of age-related parameters defining E_H and prior knowledge on their age-dependency

Parameter	**Definition**	**Age-dependency Model**
Q_H	Hepatic blood flow as a function of cardiac index	Guyton, 1991
MPPGL	mg of microsomal protein per gram of liver	Barter et al., 2008
CYP3A4 and CYP1A”	pmol of enzyme abundance	Salem et al., 2014
Liver volume	ml of liver	Johnson et al., 2005
Albumin and AAG	Plasma proteins concentration (g/L)	Johnson et al., 2006 and Sethi et al., 2015

Figure 1


Hepatic extraction
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0.001
0.01
0.1
1
10
100
10 months
Age (years)

Figure 2


1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
Hepatic extraction
High Extraction
Low Extraction
1 Day
1 Month
2 Years
12 Years
Adults
Age
Midazolam
10-fold higher CLu$_{int,H}$ than midazolam
10-fold lower CLu$_{int,H}$ than midazolam

Figure 3


A
B
1.6
1.0
0.4
0.1
0.06
0.05
0.04
Fraction of Adult
1 Day
1 Month
2 Years
12 Years
Adults
Age
Liver volume
QH
MPPGL
CYP1A2 Abundance
AAG
Albumin
CYP3A4 Abundance

Considering Age Variation when Coining Drugs as High vs Low Hepatic Extraction Ratio.

Farzaneh Salem, Khaled Abduljalil, Yoshi Kamiyama and Amin Rostami Hodjegan

Drug Metabolism & Disposition

Supplementary Material



Figure S1 E_H changes with age for midazolam, a drug with 10-fold higher and lower CLu_{int}, are minimal when the enzyme abundance (pmol per MPPGL), MPPGL and fu_B are fixed to the adult values. The slight variation around 12 years relates to higher cardiac index (cardiac output to body surface area). Cardiac index values for 1 day, 1 month, 2 years, 12 years and 25 years are 2.33, 2.35, 2.50, 2.67, 3.80 and 2.5 L/min/m^2 (Johnson et al., 2006; Guyton., 1991).

Considering Age Variation when Coining Drugs as High vs Low Hepatic Extraction Ratio.

Farzaneh Salem, Khaled Abduljalil, Yoshi Kamiyama and Amin Rostami Hodjegan

Drug Metabolism & Disposition

Table S1 Summary of covariates considered in analysing PopPK studies. However, not all of these covariates resulted in significant reduction of objective function and were included in the final model.

Covariate	Category
Post-menstrual age	Age
Postnatal age	
Post-conception age	
Starting age on breast milk	
Day of treatment	Time
Period of intubation before study entry	
Post-transplant days	
Weight (birth weight or current weight)	Size
Weight (allometric scaling, linear and exponential model)	
Body mass index	
Body surface area	
Fat free mass (Allometric scaling)	
Body length	
Head circumference	
Male and Female	Sex
Race	Ethnicity
Cratinine (Serum or clearance)	Biomarker
Billirubin (unconjugated)	
Aminotransferase	
Alkaline phosphatase	
Globulin concentration	

Considering Age Variation when Coining Drugs as High vs Low Hepatic Extraction Ratio.

Farzaneh Salem, Khaled Abduljalil, Yoshi Kamiyama and Amin Rostami Hodjegan

Drug Metabolism & Disposition

Platelet counts	
Glomerular filtration rate	
Oxygen concentration	
Nephrectomy	Clinical Condition
Systemic inflammatory response syndrome	
Critical illness	
Hepatic dysfunction	
Health status	
Apgar score at 1 minute and 5 minutes	
Birth asphyxia	
Feed intolerance	
Presence of respiratory distress syndrome	
Patent ductus arteriosus	
Respiratory support and form of support	
Infection	
Co-medication (phenobarbital, parental nutrition, diuretic, enzyme inducer, dexamethasone, nephrotoxic drug)	Therapy
Carboplatin therapy	
Surfactant therapy	
CYP2C19 inhibitors	
Route of delivery	Maternal
Prenatal smoking history,	
Current multiple pregnancy	
Antepartum haemorrhage	
Chorioamnionitis	
Preeclampsia	

Considering Age Variation when Coining Drugs as High vs Low Hepatic Extraction Ratio.

Farzaneh Salem, Khaled Abduljalil, Yoshi Kamiyama and Amin Rostami Hodjegan

Drug Metabolism & Disposition

Premature rupture of the membranes	
Genotypes (CYP2C19, 2C9, CYP2D6, OCT1)	Genotype
Study centre	Other
Inter-occasion variability	

Considering Age Variation when Coining Drugs as High vs Low Hepatic Extraction Ratio.

Farzaneh Salem, Khaled Abduljalil, Yoshi Kamiyama and Amin Rostami Hodjegan

Drug Metabolism & Disposition

Table S2 Summary of the analyses PopPK studies with significant covariates. Where interaction between covariates was considered, the relevant covariates are identified.

ID	Compound	Population	Covariates	Covariate Interaction	Reference
1	Acetaminophen	PN=1–144 days	Weight, PMA, unconjugated bilirubin	Weight & PMA & unconjugated bilirubin	(Palmer et al., 2008)
2		27-42 weeks PCA	PCA, Weight	PCA & Weight	(Allegaert et al., 2004)
3		neonates (27-45 weeks PMA)	Weight, PCA	PCA & Weight	(Allegaert et al., 2011)
4		premature - 14 years	Weight (allometric),PCA	PCA & Weight	(Anderson et al., 2005)
5		6 months-2 years	Weight	No	(Prins et al., 2008)
6		Neonates to adolescents	PNA, Weight (allometric)	PNA and Weight	(Zuppa et al., 2011)
7		neonates	Weight, PMA	description of covariates interaction in the final model was not clear	(van Ganzewinkel et al., 2014)
8		1 day -34 years	Weight -dependent exponent model	No	(Wang et al., 2014)
9		4 days to 3 months.	age, Weight	age & Weight	(Anderson et al., 2000)

10		1 day to 6 months.	Weight & PCA	Weight & PCA	(Anderson et al., 2002)
11		< 18 years children	Weight	No	(Mohammed et al., 2012)
12	Actinomycin-D	children (1.6 to 20.3 years)	Weight	No	(Mondick et al., 2008)
13		< 21 years	Weight	No	(Hill et al., 2014)
14	Acyclovir	preterm and term infants	Weight, PMA	Weight & PMA	(Sampson et al., 2014)
15		0.8–19.9 children	Weight, CrCL	Weight & CrCL	(Zeng et al., 2009)
16		0.25-17yr children	Weight, BSA, GFR, PCA, Scr	Weight & BSA & GFR & PCA & Scr	(Tod et al., 2001)
17	Amikacin	gestational ages from 24 to 41 weeks	Weight, PMA	Weight & PMA	(Sherwin et al., 2009b)
18		gestational age 24–43 weeks; postnatal age 1–30 days	Weight -dependent exponent & PNA	Weight & PNA	(De Cock et al., 2012)
19	Aminophylline	PNA=0-26 weeks	Weight, PNA	No	(Moore et al., 1989)
20	Bevacizumab	children	BMI	Weight & BMI	(Turner et al., 2014)

21	Busulfan	children	Weight	No	(Diestelhorst et al., 2014)
22		0.45-16.7 years	Weight	No	(Nguyen et al., 2004)
23		10 days to 15 years	Weight (allometric)	No	(Paci et al., 2012)
24		94 children (0.4 - 18.8 years)	BSA, Weight	No	(Trame et al., 2011)
25		0.7-13.1 years children	Allometric Weight	No	(Veal et al., 2012)
26		0.2 to 23 years	Weight	No	(Zwaveling et al., 2008)
27		age 0.1-3.3 years old	Allometric Weight, Age	Weight and age	(Savic et al., 2013)
28		0.1 to 26 years	age, WT, BSA	No	(Bartelink et al., 2012)
29	Caffeine	premature neonates 27.6 weeks GSA	Weight, PNA	Weight & PNA	(Charles et al., 2008)
30		premature neonates	Weight, LGA, PNA and parental nutrition	GA & Weight &PNA	(Falcao et al., 1997)
31		premature neonates <32 GW	Weight, PNA	No	(Lee et al., 1997)

32		premature neonates < 34 GW	Weight	No	(Lee et al., 2002)
33	Canrenoate	2 days-0.85 years	Weight, PMA	Weight & PMA	(Suyagh et al., 2013)
34		2 days to 10 years children	Weight	No	(Suyagh et al., 2012)
35	carboplatin	2 m to 18 years	Weight, SeCr, nephrectomy	Weight & SeCr & nephrectomy	(Chatelut et al., 1996)
36	cefepime	Premature & infants <4 mon.	Weight, SeCr	Weight & SeCr	(Capparelli et al., 2005)
37	cefozopran	children	Weight	No	(Ikawa et al., 2009)
38	ceftazidime	10–45 years	Allometric scaling by FFM	No	(Bulitta et al., 2010)
39	ciprofloxacin	0.27-16.9 years	Weight, Age	Weight & Age	(Rajagopalan and Gastonguay, 2003)
40		6 - 16 years	Weight	No	(Schaefer et al., 1996)
41	Clindamycin	Premature Infants to Adolescents	Weight, PMA	Weight & PMA	(Gonzalez et al., 2014)
42	Clonidine	0-15 years	Weight	need full paper	(Potts et al., 2007)

43	cyclophosphamide	age range 1.30 – 9.37 years	GFR, gender	No	(McCune et al., 2009)
44	cyclosporine	children	BSA, posttransplant Days	BSA & posttransplant Days	(Zhou et al., 2013)
45		0.36 - 17.5 years	Weight, Cholesterol, Hct, Scr	Weight & Cholesterol & Hct & Scr	(Fanta et al., 2007)
46		0.9 -20 years	Weight, age, co-med (itraconazole & tobramycine)	description of covariates interaction in the final model was not clear	(Schrauder et al., 2009)
47	cytosine arabinoside	52 paediatric patients	AGE, BSA	AGE & BSA	(Periclou and Avramis, 1996)
48	daunorubicin	children	Weight	No	(Hempel et al., 2003)
49	dexmedetomidine	children	Weight, study centre	No	(Petroz et al., 2006)
50	Diclofenac	aged 1-14 years	Weight	No	(Standing et al., 2011)
51	digoxin	0.33 to 15 years children	SeCr	No	(el-Desoky et al., 2005)
52	doxorubicin	children older than 3 years	BSA, inter-occasion varaibility	No	(Kontny et al., 2013)

53	esomeprazole	0-17 years	Weight, age	description of covariates interaction in the final model was not clear	(Sandstrom et al., 2012)
54	Etomidate	0.53-13.21 years	Allometric WT, Age	Weight & Age	(Lin et al., 2012)
55		14 weeks to 16.7 years	Weight (alometry)	No	(Urien et al., 2011)
56	fluconazole	PNA=0.14 to 12.6 weeks	Weight, postnatal age, gestational age at birth, SeCr	Weight & GA & PNA & Scr	(Wade et al., 2008)
57	flurbiprofen	3 mon. - 13 years children	Weight	No	(Kumpulainen et al., 2010)
58	Ganciclovir	PNA= 8-34 days	WT	No	(Acosta et al., 2007)
59	Gentamicin	14 - 81 years cancer patient	creatinine clearance	No	(Rosario et al., 1998)
			WT, PNA	WT & PNA	(De Cock et al., 2014)
60		neonates	WT , PNA	WT & PNA	(Sherwin et al., 2009a)

61		premature & term neonates(PMA=24.2-42.4wks)	WT, PNA, gestational age	WT, PNA & GA	(Fuchs et al., 2014)
62	hydrocortisone	critically ill neonates	WT, PMA	WT & PMA	(Vezina et al., 2014)
63	indomethacin	premature neonates	WT	No	(Al Za'abi et al., 2007)
64		PNA=1-77 days	WT, PNA	WT & APNA	(Smyth et al., 2004)
65	Irinotecan	children	WT, Age and bilirubin	WT & Age & bilirubin	(Thompson et al., 2008)
66	Ketamin	1.5-14 years children (and adult)	WT	No	(Herd et al., 2007)
67	Lamivudine	2 days to 18 years	WT (alometry), PMA (maturation)	WT & PMA	(Bouazza et al., 2011)
68	Levofloxacin	paediatric & adult	WT, Age	WT & Age	(Li et al., 2010)
69	levetiracetam	PNA=1 - 5 days	WT, PNA	WT & PNA	(Sharpe et al., 2012)
70	lorazepam	3 mon - <18 years	WT	No	(Chamberlain et al., 2012)

71	Melphalan	children	WT, GFR, carboplatin therapy	No	(Nath et al., 2007)
72	Meropenem	GA=29 - 42 weeks	CrCL, WT	No	(van den Anker et al., 2009)
73	Methotrexate	children	WT, Age	No	(Colom et al., 2009)
74	Metronidazole	32 pre-term	WT, PMA	WT & PMA	(Suyagh et al., 2011)
75	Micafungin	children and adult	WT, platelet counts	No	(Tabata et al., 2006)
76	Midazolam	paediatric intensive care unit	WT	No	(Bienert et al., 2013)
77		neonates	WT, GA	WT & GA	(Burtin et al., 1994)
78		1 month to 17 years children	critical illness, WT	critical illness & WT	(Ince et al., 2012)
79		Premature Infants to Adolescents	WT, WT-dependent exponent of allometric exponent function	No	(Ince et al., 2013)
80		6 months to < 16 years	Age	No	(Reed et al., 2001)

81		2 month to 17 years children	WT-dependent exponent function	No	(Ince et al., 2012)
82		paediatric intensive care unit	WT (albumin was added, but removed from the final model not significant)	No	(Bienert et al., 2013)
83	Montelukast	6 - 86 years	WT	No	(Ramakrishnan et al., 2005)
84	Morphine	children	WT, OCT1 genotypes	WT & OCT1 genotypes	(Fukuda et al., 2013)
85		preterm - < 3 years	WT, PNA	PNA (stratified)	(Knibbe et al., 2009)
86		0 - 3 year children	WT, PNA, creatinine, bilirubin,	WT & PNA	(Bouwmeester et al., 2004)
87	Mycophenolic	children and young people	WT, ciclosporin	WT & ciclosporin	(Zeng et al., 2010)
88	Myo-inositol	Infants born in 23-29 weeks of gestation	WT (allometric), CrCL, gestational age	No	(Phelps et al., 2013)
89	Netilmicin	2 to 28 days	cWT, PMA	cWT & PMA	(Sherwin et al., 2008)

90	Omeprazole	critically ill children	WT (allometry)	No	(Solana et al., 2014)
91	Ondansetron	2–38 years	Wt, Age, Sex,	sex & age + wt	(de Alwis et al., 1998)
92	Palivizumab	Preterm infants to adult	age,WT, lung disease, race, antidrug antibody titer	WT, Age, race, lung disease and antidrug antibody titer	(Robbie et al., 2012)
93	Pantoprazole	0.025-16 years	WT, GA, Age, race, gender, 2C9 polymorphisms	WT, GA, Age, race, gender, 2C9 polymorphisms	(Knebel et al., 2011)
94		10 days to 16.4 years	WT, Age, hepatic dysfunction, CYP2C19 inhibitors , systemic inflammatory response syndrome	WT, Age, DDI , SIRS, Hepatic dysfunction	(Pettersen et al., 2009)
95	Phenobarbital	PNA= 0.0–206 days	WT (allometric)	No	(Marsot et al., 2014)
96	Phenytoin	neonates and infants	WT, PNA	WT & PNA	(Al Za'abi et al., 2006)
97		include children	WT	No	(Tanaka et al., 2013)

98	Propofol	obese children and adolescents	WT	No	(Diepstraten et al., 2012)
99		0.25-88 years	WT, age, sex, health status	WT & Age	(Eleveld et al., 2014)
100		3 - 11 years	WT	No	(Kataria et al., 1994)
101		children	WT	No	(Knibbe et al., 2002)
102		pre-term to adults	WT	No	(Wang et al., 2012)
103		from 2.0 to 88 year	WT	No	(Schuttler and Ihmsen, 2000)
104		1 week to 12 year	WT, Cardiac surgery	No (or yes WT & Cardiac Surgery)	(Rigby-Jones et al., 2002)
105	Ranitidine	critically ill children (age: 0.042 - 15.51 years)	WT (allometry)	WT & Cardiac failure/surgery	(Hawwa et al., 2013)
106	Sildenafil	new-born (11-71 hr)	PNA	No	(Mukherjee et al., 2009)
107	Tacrolimus	1-14 years children	Age	No	(Sam et al., 2000)
108		children	WT, serum creatinine;	WT & SeCr	(Wallin et al., 2009)

109	Theophylline	premature neonates	WT, PNA	No	(Lee et al., 1996)
110	Tobramycin	children	WT	No	(Hennig et al., 2008)
111		0.1-18.8 years	WT	No	(Sherwin et al., 2014)
			WT, PNA	WT & PNA	(De Cock et al., 2014)
112	Tramadol	children (0–3 months) and adult (23-57 year)	WT, PCA	WT & PCA	(Allegaert et al., 2005)
113	Tranexamic acid	1.0 - 12 years	WT (alometry)	No	(Grassin-Delyle et al., 2013)
114	Valproic acid	1 to 17 years	Weight	No	(Williams et al., 2012)
115	Vancomycin	neonates	current Weight, birth Weight, SeCr, PNA	current weight, birth weight, SeCr & PNA	(Zhao et al., 2013)
116			Weight, PNA	Weight & PNA	(De Cock et al., 2014)
117	Voriconazole	2 to <12 years	Weight, age, CYP2C19 phenotypes, ALT	Weight, age, 2C19 phenotype, ALT	(Karlsson et al., 2009)
118		2 years to adult	Weight, age, CYP2C19 phenotypes	Weight, age, CYP2C19 phenotypes	(Friberg et al., 2012)
119		2 to 11 years	Weight, 2C19 phenotype	Weight & 2C19 phenotype	(Walsh et al., 2004)

120	2–11 years children	Weight, 2C19 phenotypes, aminotransferase, alkaline phosphatase	Weight & 2C9 phenotype, alanine amino transferase, alkaline phosphatase	(Wahlby et al., 2004)

SeCr: serum creatinine

References

Acosta EP, Brundage RC, King JR, Sanchez PJ, Sood S, Agrawal V, Homans J, Jacobs RF, Lang D, Romero JR, Griffin J, Cloud G, Whitley R and Kimberlin DW (2007) Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. *Clin Pharmacol Ther* **81:**867-872.

Al Za'abi M, Donovan T, Tudehope D, Woodgate P, Collie LA and Charles B (2007) Orogastric and intravenous indomethacin administration to very premature neonates with patent ductus arteriosus: population pharmacokinetics, absolute bioavailability, and treatment outcome. *Ther Drug Monit* **29:**807-814.

Al Za'abi M, Lanner A, Xiaonian X, Donovan T and Charles B (2006) Application of routine monitoring data for determination of the population pharmacokinetics and enteral bioavailability of phenytoin in neonates and infants with seizures. *Ther Drug Monit* **28:**793-799.

Allegaert K, Anderson BJ, Naulaers G, de Hoon J, Verbesselt R, Debeer A, Devlieger H and Tibboel D (2004) Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates. *Eur J Clin Pharmacol* **60:**191-197.

Allegaert K, Anderson BJ, Verbesselt R, Debeer A, de Hoon J, Devlieger H, Van Den Anker JN and Tibboel D (2005) Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 2D6 activity. *Br J Anaesth* **95:**231-239.

Allegaert K, Palmer GM and Anderson BJ (2011) The pharmacokinetics of intravenous paracetamol in neonates: size matters most. *Arch Dis Child* **96:**575-580.

Anderson BJ, Pons G, Autret-Leca E, Allegaert K and Boccard E (2005) Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. *Paediatr Anaesth* **15:**282-292.

Anderson BJ, van Lingen RA, Hansen TG, Lin YC and Holford NH (2002) Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. *Anesthesiology* **96:**1336-1345.

Anderson BJ, Woollard GA and Holford NH (2000) A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. *Br J Clin Pharmacol* **50:**125-134.

Bartelink IH, Boelens JJ, Bredius RG, Egberts AC, Wang C, Bierings MB, Shaw PJ, Nath CE, Hempel G, Zwaveling J, Danhof M and Knibbe CA (2012) Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. *Clin Pharmacokinet* **51:**331-345.

Bienert A, Bartkowska-Sniatkowska A, Wiczling P, Rosada-Kurasinska J, Grzeskowiak M, Zaba C, Tezyk A, Sokolowska A, Kaliszan R and Grzeskowiak E (2013) Assessing circadian rhythms during prolonged midazolam infusion in the pediatric intensive care unit (PICU) children. *Pharmacol Rep* **65:**107-121.

Bouazza N, Hirt D, Blanche S, Frange P, Rey E, Treluyer JM and Urien S (2011) Developmental pharmacokinetics of lamivudine in 580 pediatric patients ranging from neonates to adolescents. *Antimicrob Agents Chemother* **55:**3498-3504.

Bouwmeester NJ, Anderson BJ, Tibboel D and Holford NH (2004) Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. *Br J Anaesth* **92:**208-217.

Bulitta JB, Landersdorfer CB, Huttner SJ, Drusano GL, Kinzig M, Holzgrabe U, Stephan U and Sorgel F (2010) Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. *Antimicrob Agents Chemother* **54:**1275-1282.

Burtin P, Jacqz-Aigrain E, Girard P, Lenclen R, Magny JF, Betremieux P, Tehiry C, Desplanques L and Mussat P (1994) Population pharmacokinetics of midazolam in neonates. *Clin Pharmacol Ther* **56:**615-625.

Capparelli E, Hochwald C, Rasmussen M, Parham A, Bradley J and Moya F (2005) Population pharmacokinetics of cefepime in the neonate. *Antimicrob Agents Chemother* **49:**2760-2766.

Chamberlain JM, Capparelli EV, Brown KM, Vance CW, Lillis K, Mahajan P, Lichenstein R, Stanley RM, Davis CO, Gordon S, Baren JM and van den Anker JN (2012) Pharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticus. *J Pediatr* **160:**667-672 e662.

Charles BG, Townsend SR, Steer PA, Flenady VJ, Gray PH and Shearman A (2008) Caffeine citrate treatment for extremely premature infants with apnea: population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring. *Ther Drug Monit* **30:**709-716.

Chatelut E, Boddy AV, Peng B, Rubie H, Lavit M, Dezeuze A, Pearson AD, Roche H, Robert A, Newell DR and Canal P (1996) Population pharmacokinetics of carboplatin in children. *Clin Pharmacol Ther* **59:**436-443.

Colom H, Farre R, Soy D, Peraire C, Cendros JM, Pardo N, Torrent M, Domenech J and Mangues MA (2009) Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma. *Ther Drug Monit* **31:**76-85.

de Alwis DP, Aarons L and Palmer JL (1998) Population pharmacokinetics of ondansetron: a covariate analysis. *Br J Clin Pharmacol* **46:**117-125.

De Cock RF, Allegaert K, Schreuder MF, Sherwin CM, de Hoog M, van den Anker JN, Danhof M and Knibbe CA (2012) Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. *Clin Pharmacokinet* **51:**105-117.

De Cock RF, Allegaert K, Sherwin CM, Nielsen EI, de Hoog M, van den Anker JN, Danhof M and Knibbe CA (2014) A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. *Pharm Res* **31:**754-767.

Diepstraten J, Chidambaran V, Sadhasivam S, Esslinger HR, Cox SL, Inge TH, Knibbe CA and Vinks AA (2012) Propofol clearance in morbidly obese children and adolescents: influence of age and body size. *Clin Pharmacokinet* **51:**543-551.

Diestelhorst C, Boos J, McCune JS and Hempel G (2014) Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM(R) model to optimize dosing. *Eur J Clin Pharmacol* **70:**839-847.

el-Desoky ES, Madabushi R, Amry Sel D, Bhattaram VA and Derendorf H (2005) Application of two-point assay of digoxin serum concentration in studying population pharmacokinetics in Egyptian pediatric patients with heart failure: does it make sense? *Am J Ther* **12:**320-327.

Eleveld DJ, Proost JH, Cortinez LI, Absalom AR and Struys MM (2014) A general purpose pharmacokinetic model for propofol. *Anesth Analg* **118:**1221-1237.

Falcao AC, Fernandez de Gatta MM, Delgado Iribarnegaray MF, Santos Buelga D, Garcia MJ, Dominguez-Gil A and Lanao JM (1997) Population pharmacokinetics of caffeine in premature neonates. *Eur J Clin Pharmacol* **52:**211-217.

Fanta S, Jonsson S, Backman JT, Karlsson MO and Hoppu K (2007) Developmental pharmacokinetics of ciclosporin--a population pharmacokinetic study in paediatric renal transplant candidates. *Br J Clin Pharmacol* **64:**772-784.

Friberg LE, Ravva P, Karlsson MO and Liu P (2012) Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. *Antimicrob Agents Chemother* **56:**3032-3042.

Fuchs A, Guidi M, Giannoni E, Werner D, Buclin T, Widmer N and Csajka C (2014) Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. *Br J Clin Pharmacol* **78:**1090-1101.

Fukuda T, Chidambaran V, Mizuno T, Venkatasubramanian R, Ngamprasertwong P, Olbrecht V, Esslinger HR, Vinks AA and Sadhasivam S (2013) OCT1 genetic variants influence the pharmacokinetics of morphine in children. *Pharmacogenomics* **14:**1141-1151.

Gonzalez D, Melloni C, Yogev R, Poindexter BB, Mendley SR, Delmore P, Sullivan JE, Autmizguine J, Lewandowski A, Harper B, Watt KM, Lewis KC, Capparelli EV, Benjamin DK, Jr. and Cohen-Wolkowiez M (2014) Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents. *Clin Pharmacol Ther* **96:**429-437.

Grassin-Delyle S, Couturier R, Abe E, Alvarez JC, Devillier P and Urien S (2013) A practical tranexamic acid dosing scheme based on population pharmacokinetics in children undergoing cardiac surgery. *Anesthesiology* **118:**853-862.

Guyton AC (1991) *Cardiac Output, Venous Return, and Their Regulation.* In: Textbook of Medical Physiology, 8th ed. W.B.Saunders Company, Philadelphia, pp. 221-233.

Hawwa AF, Westwood PM, Collier PS, Millership JS, Yakkundi S, Thurley G, Shields MD, Nunn AJ, Halliday HL and McElnay JC (2013) Prophylactic ranitidine treatment in critically ill children--a population pharmacokinetic study. *Br J Clin Pharmacol* **75:**1265-1276.

Hempel G, Reinhardt D, Creutzig U and Boos J (2003) Population pharmacokinetics of liposomal daunorubicin in children. *Br J Clin Pharmacol* **56:**370-377.

Hennig S, Norris R and Kirkpatrick CM (2008) Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study. *Br J Clin Pharmacol* **65:**502-510.

Herd DW, Anderson BJ and Holford NH (2007) Modeling the norketamine metabolite in children and the implications for analgesia. *Paediatr Anaesth* **17:**831-840.

Hill CR, Cole M, Errington J, Malik G, Boddy AV and Veal GJ (2014) Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer. *Clin Pharmacokinet* **53:**741-751.

Ikawa K, Kozumi T, Ikeda K, Morikawa N and Kobayashi R (2009) Population pharmacokinetic modeling and pharmacodynamic assessment of cefozopran in pediatric patients. *Jpn J Antibiot* **62:**435-444.

Ince I, de Wildt SN, Peeters MY, Murry DJ, Tibboel D, Danhof M and Knibbe CA (2012) Critical illness is a major determinant of midazolam clearance in children aged 1 month to 17 years. *Ther Drug Monit* **34:**381-389.

Ince I, de Wildt SN, Wang C, Peeters MY, Burggraaf J, Jacqz-Aigrain E, van den Anker JN, Tibboel D, Danhof M and Knibbe CA (2013) A novel maturation function for clearance of the cytochrome P450 3A substrate midazolam from preterm neonates to adults. *Clin Pharmacokinet* **52:**555-565.

Johnson TN, Rostami-Hodjegan A and Tucker GT (2006) Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. *Clin Pharmacokinet* **45:**931-956.

Karlsson MO, Lutsar I and Milligan PA (2009) Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. *Antimicrob Agents Chemother* **53:**935-944.

Kataria BK, Ved SA, Nicodemus HF, Hoy GR, Lea D, Dubois MY, Mandema JW and Shafer SL (1994) The pharmacokinetics of propofol in children using three different data analysis approaches. *Anesthesiology* **80:**104-122.

Knebel W, Tammara B, Udata C, Comer G, Gastonguay MR and Meng X (2011) Population pharmacokinetic modeling of pantoprazole in pediatric patients from birth to 16 years. *J Clin Pharmacol* **51:**333-345.

Knibbe CA, Krekels EH, van den Anker JN, DeJongh J, Santen GW, van Dijk M, Simons SH, van Lingen RA, Jacqz-Aigrain EM, Danhof M and Tibboel D (2009) Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. *Clin Pharmacokinet* **48:**371-385.

Knibbe CA, Melenhorst-de Jong G, Mestrom M, Rademaker CM, Reijnvaan AF, Zuideveld KP, Kuks PF, van Vught H and Danhof M (2002) Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. *Br J Clin Pharmacol* **54:**415-422.

Kontny NE, Wurthwein G, Joachim B, Boddy AV, Krischke M, Fuhr U, Thompson PA, Jorger M, Schellens JH and Hempel G (2013) Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years. *Cancer Chemother Pharmacol* **71:**749-763.

Kumpulainen E, Valitalo P, Kokki M, Lehtonen M, Hooker A, Ranta VP and Kokki H (2010) Plasma and cerebrospinal fluid pharmacokinetics of flurbiprofen in children. *Br J Clin Pharmacol* **70:**557-566.

Lee HS, Khoo YM, Chirino-Barcelo Y, Tan KL and Ong D (2002) Caffeine in apnoeic Asian neonates: a sparse data analysis. *Br J Clin Pharmacol* **54:**31-37.

Lee TC, Charles B, Steer P, Flenady V and Shearman A (1997) Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. *Clin Pharmacol Ther* **61:**628-640.

Lee TC, Charles BG, Steer PA, Flenady VJ and Grant TC (1996) Theophylline population pharmacokinetics from routine monitoring data in very premature infants with apnoea. *Br J Clin Pharmacol* **41:**191-200.

Li F, Nandy P, Chien S, Noel GJ and Tornoe CW (2010) Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. *Antimicrob Agents Chemother* **54:**375-379.

Lin L, Zhang JW, Huang Y, Bai J, Cai MH and Zhang MZ (2012) Population pharmacokinetics of intravenous bolus etomidate in children over 6 months of age. *Paediatr Anaesth* **22:**318-326.

Marsot A, Brevaut-Malaty V, Vialet R, Boulamery A, Bruguerolle B and Simon N (2014) Pharmacokinetics and absolute bioavailability of phenobarbital in neonates and young infants, a population pharmacokinetic modelling approach. *Fundam Clin Pharmacol* **28:**465-471.

McCune JS, Salinger DH, Vicini P, Oglesby C, Blough DK and Park JR (2009) Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group. *J Clin Pharmacol* **49:**88-102.

Mohammed BS, Engelhardt T, Cameron GA, Cameron L, Hawksworth GM, Hawwa AF, McElnay J, Helms PJ and McLay JS (2012) Population pharmacokinetics of single-dose intravenous paracetamol in children. *Br J Anaesth* **108:**823-829.

Mondick JT, Gibiansky L, Gastonguay MR, Skolnik JM, Cole M, Veal GJ, Boddy AV, Adamson PC and Barrett JS (2008) Population pharmacokinetic investigation of actinomycin-D in children and young adults. *J Clin Pharmacol* **48:**35-42.

Moore ES, Faix RG, Banagale RC and Grasela TH (1989) The population pharmacokinetics of theophylline in neonates and young infants. *J Pharmacokinet Biopharm* **17:**47-66.

Mukherjee A, Dombi T, Wittke B and Lalonde R (2009) Population pharmacokinetics of sildenafil in term neonates: evidence of rapid maturation of metabolic clearance in the early postnatal period. *Clin Pharmacol Ther* **85:**56-63.

Nath CE, Shaw PJ, Montgomery K and Earl JW (2007) Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. *Br J Clin Pharmacol* **64:**151-164.

Nguyen L, Fuller D, Lennon S, Leger F and Puozzo C (2004) I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. *Bone Marrow Transplant* **33:**979-987.

Paci A, Vassal G, Moshous D, Dalle JH, Bleyzac N, Neven B, Galambrun C, Kemmel V, Abdi ZD, Broutin S, Petain A and Nguyen L (2012) Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation. *Ther Drug Monit* **34:**198-208.

Palmer GM, Atkins M, Anderson BJ, Smith KR, Culnane TJ, McNally CM, Perkins EJ, Chalkiadis GA and Hunt RW (2008) I.V. acetaminophen pharmacokinetics in neonates after multiple doses. *Br J Anaesth* **101:**523-530.

Periclou AP and Avramis VI (1996) NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias. *Cancer Chemother Pharmacol* **39:**42-50.

Petroz GC, Sikich N, James M, van Dyk H, Shafer SL, Schily M and Lerman J (2006) A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children. *Anesthesiology* **105:**1098-1110.

Pettersen G, Mouksassi MS, Theoret Y, Labbe L, Faure C, Nguyen B and Litalien C (2009) Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients. *Br J Clin Pharmacol* **67:**216-227.

Phelps DL, Ward RM, Williams RL, Watterberg KL, Laptook AR, Wrage LA, Nolen TL, Fennell TR, Ehrenkranz RA, Poindexter BB, Michael Cotten C, Hallman MK, Frantz ID, 3rd, Faix RG, Zaterka-Baxter KM, Das A, Bethany Ball M, Michael O'Shea T,

Backstrom Lacy C, Walsh MC, Shankaran S, Sanchez PJ, Bell EF and Higgins RD (2013) Pharmacokinetics and safety of a single intravenous dose of myo-inositol in preterm infants of 23-29 wk. *Pediatr Res* **74:**721-729.

Potts AL, Larsson P, Eksborg S, Warman G, Lonnqvist PA and Anderson BJ (2007) Clonidine disposition in children; a population analysis. *Paediatr Anaesth* **17:**924-933.

Prins SA, Van Dijk M, Van Leeuwen P, Searle S, Anderson BJ, Tibboel D and Mathot RA (2008) Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery. *Paediatr Anaesth* **18:**582-592.

Rajagopalan P and Gastonguay MR (2003) Population pharmacokinetics of ciprofloxacin in pediatric patients. *J Clin Pharmacol* **43:**698-710.

Ramakrishnan R, Migoya E and Knorr B (2005) A population pharmacokinetic model for montelukast disposition in adults and children. *Pharm Res* **22:**532-540.

Reed MD, Rodarte A, Blumer JL, Khoo KC, Akbari B, Pou S, Pharmd and Kearns GL (2001) The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration. *J Clin Pharmacol* **41:**1359-1369.

Rigby-Jones AE, Nolan JA, Priston MJ, Wright PM, Sneyd JR and Wolf AR (2002) Pharmacokinetics of propofol infusions in critically ill neonates, infants, and children in an intensive care unit. *Anesthesiology* **97:**1393-1400.

Robbie GJ, Zhao L, Mondick J, Losonsky G and Roskos LK (2012) Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. *Antimicrob Agents Chemother* **56:**4927-4936.

Rosario MC, Thomson AH, Jodrell DI, Sharp CA and Elliott HL (1998) Population pharmacokinetics of gentamicin in patients with cancer. *Br J Clin Pharmacol* **46:**229-236.

Sam WJ, Aw M, Quak SH, Lim SM, Charles BG, Chan SY and Ho PC (2000) Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. *Br J Clin Pharmacol* **50:**531-541.

Sampson MR, Bloom BT, Lenfestey RW, Harper B, Kashuba AD, Anand R, Benjamin DK, Jr., Capparelli E, Cohen-Wolkowiez M and Smith PB (2014) Population pharmacokinetics of intravenous acyclovir in preterm and term infants. *Pediatr Infect Dis J* **33:**42-49.

Sandstrom M, Davidson G, Tolia V, Sullivan JE, Langstrom G, Lundborg P and Brown K (2012) Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age. *Clin Ther* **34:**1828-1838.

Savic RM, Cowan MJ, Dvorak CC, Pai SY, Pereira L, Bartelink IH, Boelens JJ, Bredius RG, Wynn RF, Cuvelier GD, Shaw PJ, Slatter MA and Long-Boyle J (2013) Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation. *Biol Blood Marrow Transplant* **19:**1608-1614.

Schaefer HG, Stass H, Wedgwood J, Hampel B, Fischer C, Kuhlmann J and Schaad UB (1996) Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. *Antimicrob Agents Chemother* **40:**29-34.

Schrauder A, Saleh S, Sykora KW, Hoy H, Welte K, Boos J, Hempel G and Grigull L (2009) Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem-cell transplant recipients. The trough level is not enough. *Pediatr Transplant* **13:**444-450.

Schuttler J and Ihmsen H (2000) Population pharmacokinetics of propofol: a multicenter study. *Anesthesiology* **92:**727-738.

Sharpe CM, Capparelli EV, Mower A, Farrell MJ, Soldin SJ and Haas RH (2012) A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. *Pediatr Res* **72:**43-49.

Sherwin CM, Broadbent RS, Medlicott NJ and Reith DM (2008) Individualising netilmicin dosing in neonates. *Eur J Clin Pharmacol* **64:**1201-1208.

Sherwin CM, Kostan E, Broadbent RS, Medlicott NJ and Reith DM (2009a) Evaluation of the effect of intravenous volume expanders upon the volume of distribution of gentamicin in septic neonates. *Biopharm Drug Dispos* **30:**276-280.

Sherwin CM, Svahn S, Van der Linden A, Broadbent RS, Medlicott NJ and Reith DM (2009b) Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. *Eur J Clin Pharmacol* **65:**705-713.

Sherwin CM, Zobell JT, Stockmann C, McCrory BE, Wisdom M, Young DC, Olson J, Ampofo K and Spigarelli MG (2014) Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis. *J Pharmacokinet Pharmacodyn* **41:**71-79.

Smyth JM, Collier PS, Darwish M, Millership JS, Halliday HL, Petersen S and McElnay JC (2004) Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study. *Br J Clin Pharmacol* **58:**249-258.

Solana MJ, Colom H, Lopez-Herce J, Urbano J, Gonzalez R, Lopez J, Manzanares C and Carrillo A (2014) Population pharmacokinetics of omeprazole in critically ill pediatric patients. *Ther Drug Monit* **36:**519-527.

Standing JF, Tibboel D, Korpela R and Olkkola KT (2011) Diclofenac pharmacokinetic meta-analysis and dose recommendations for surgical pain in children aged 1-12 years. *Paediatr Anaesth* **21:**316-324.

Suyagh M, Collier PS, Millership JS, Iheagwaram G, Millar M, Halliday HL and McElnay JC (2011) Metronidazole population pharmacokinetics in preterm neonates using dried blood-spot sampling. *Pediatrics* **127:**e367-374.

Suyagh M, Hawwa AF, Collier PS, Millership JS, Kole P, Millar M, Shields MD, Halliday HL and McElnay JC (2012) Population pharmacokinetic model of canrenone after intravenous administration of potassium canrenoate to paediatric patients. *Br J Clin Pharmacol* **74:**864-872.

Suyagh M, Hawwa AF, Collier PS, Millership JS, Kole P, Millar M, Shields MD, Halliday HL and McElnay JC (2013) Potassium canrenoate treatment in paediatric patients: a population pharmacokinetic study using novel dried blood spot sampling. *J Hypertens* **31:**1901-1908.

Tabata K, Katashima M, Kawamura A, Kaibara A and Tanigawara Y (2006) Population pharmacokinetic analysis of micafungin in Japanese patients with fungal infections. *Drug Metab Pharmacokinet* **21:**324-331.

Tanaka J, Kasai H, Shimizu K, Shimasaki S and Kumagai Y (2013) Population pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients, adult patients, and healthy volunteers. *Eur J Clin Pharmacol* **69:**489-497.

Thompson PA, Gupta M, Rosner GL, Yu A, Barrett J, Bomgaars L, Bernstein ML, Blaney SM and Mondick J (2008) Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group. *Cancer Chemother Pharmacol* **62:**1027-1037.

Tod M, Lokiec F, Bidault R, De Bony F, Petitjean O and Aujard Y (2001) Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. *Antimicrob Agents Chemother* **45:**150-157.

Trame MN, Bergstrand M, Karlsson MO, Boos J and Hempel G (2011) Population pharmacokinetics of busulfan in children: increased evidence for body surface area

and allometric body weight dosing of busulfan in children. *Clin Cancer Res* **17:**6867-6877.

Turner DC, Navid F, Daw NC, Mao S, Wu J, Santana VM, Neel M, Rao B, Willert JR, Loeb DM, Harstead KE, Throm SL, Freeman BB, 3rd and Stewart CF (2014) Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing. *Clin Cancer Res* **20:**2783-2792.

Urien S, Doz F, Giraud C, Rey E, Gentet JC, Chastagner P, Vassal G, Corradini N, Auvrignon A, Leblond P, Rubie H and Treluyer JM (2011) Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect. *Cancer Chemother Pharmacol* **67:**597-603.

van den Anker JN, Pokorna P, Kinzig-Schippers M, Martinkova J, de Groot R, Drusano GL and Sorgel F (2009) Meropenem pharmacokinetics in the newborn. *Antimicrob Agents Chemother* **53:**3871-3879.

van Ganzewinkel C, Derijks L, Anand KJ, van Lingen RA, Neef C, Kramer BW and Andriessen P (2014) Multiple intravenous doses of paracetamol result in a predictable pharmacokinetic profile in very preterm infants. *Acta Paediatr* **103:**612-617.

Veal GJ, Nguyen L, Paci A, Riggi M, Amiel M, Valteau-Couanet D, Brock P, Ladenstein R and Vassal G (2012) Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial. *Eur J Cancer* **48:**3063-3072.

Vezina HE, Ng CM, Vazquez DM, Barks JD and Bhatt-Mehta V (2014) Population pharmacokinetics of unbound hydrocortisone in critically ill neonates and infants with vasopressor-resistant hypotension. *Pediatr Crit Care Med* **15:**546-553.

Wade KC, Wu D, Kaufman DA, Ward RM, Benjamin DK, Jr., Sullivan JE, Ramey N, Jayaraman B, Hoppu K, Adamson PC, Gastonguay MR and Barrett JS (2008)

Population pharmacokinetics of fluconazole in young infants. *Antimicrob Agents Chemother* **52:**4043-4049.

Wahlby U, Thomson AH, Milligan PA and Karlsson MO (2004) Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis. *Br J Clin Pharmacol* **58:**367-377.

Wallin JE, Friberg LE, Fasth A and Staatz CE (2009) Population pharmacokinetics of tacrolimus in pediatric hematopoietic stem cell transplant recipients: new initial dosage suggestions and a model-based dosage adjustment tool. *Ther Drug Monit* **31:**457-466.

Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, Milligan P and Wood N (2004) Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. *Antimicrob Agents Chemother* **48:**2166-2172.

Wang C, Allegaert K, Tibboel D, Danhof M, van der Marel CD, Mathot RA and Knibbe CA (2014) Population pharmacokinetics of paracetamol across the human age-range from (pre)term neonates, infants, children to adults. *J Clin Pharmacol* **54:**619-629.

Wang C, Peeters MY, Allegaert K, Blusse van Oud-Alblas HJ, Krekels EH, Tibboel D, Danhof M and Knibbe CA (2012) A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. *Pharm Res* **29:**1570-1581.

Williams JH, Jayaraman B, Swoboda KJ and Barrett JS (2012) Population pharmacokinetics of valproic acid in pediatric patients with epilepsy: considerations for dosing spinal muscular atrophy patients. *J Clin Pharmacol* **52:**1676-1688.

Zeng L, Blair EY, Nath CE, Shaw PJ, Earl JW, Stephen K, Montgomery K, Coakley JC, Hodson E, Stormon M and McLachlan AJ (2010) Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation. *Br J Clin Pharmacol* **70:**567-579.

Zeng L, Nath CE, Blair EY, Shaw PJ, Stephen K, Earl JW, Coakley JC and McLachlan AJ (2009) Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. *Antimicrob Agents Chemother* **53:**2918-2927.

Zhao W, Lopez E, Biran V, Durrmeyer X, Fakhoury M and Jacqz-Aigrain E (2013) Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. *Arch Dis Child* **98:**449-453.

Zhou Y, Sheng XY, Xu JY, Bi SS, Lu W and Cui YM (2013) Population pharmacokinetic study of cyclosporine in the hematopoietic stem cell transplant recipients. *Int J Clin Pharmacol Ther* **51:**568-575.

Zuppa AF, Hammer GB, Barrett JS, Kenney BF, Kassir N, Mouksassi S and Royal MA (2011) Safety and population pharmacokinetic analysis of intravenous acetaminophen in neonates, infants, children, and adolescents with pain or Fever. *J Pediatr Pharmacol Ther* **16:**246-261.

Zwaveling J, Press RR, Bredius RG, van Derstraaten TR, den Hartigh J, Bartelink IH, Boelens JJ and Guchelaar HJ (2008) Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. *Ther Drug Monit* **30:**504-510.